International Internal Medicine Journal(IIMJ)

Southern Sydney Haematology Faculty of Science, Medicine and Health University of Wollongong, Australia

Publications

• Research Article   
  Hydroxyurea: An Old Drug in Need of New Clinical Trials in Myeloproliferative Neoplasms?
  Author(s): Arumugam Manoharan* and Sonia I Enggist
  
  Hydroxyurea (Hu) has been a front-line therapeutic agent for myeloproliferative neoplasms (MPN) for many years and still enjoys the endorsement of experts in the field. However, several publications have reported sub-optimal response, the need for treatment interruption because of cytopenias and lack of sustained response. In all these studies, Hu was used as continuous therapy at a daily dose ranging from 500mg to 3000mg. At our Centre we have used Hu as intermittent therapy (akin to schedules used in patients with solid tumours) at 20-30mg/Kg doses, given as a single dose, twice or thrice weekly. We have consistently observed sustained responses without troublesome cytopenias. Concurrent anti-platelet therapy was given on the basis of the results of whole blood platelet aggregation studies, achieving effective thromboprophylaxis. In this report we present our experience in 118 patie.. Read More»
  

  Abstract HTML PDF